Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy [1]

Journal of Clinical Psychopharmacology

Volumn 21, Issue 6, 2001, Pages 616-618

  Brunswick, D J ^a   Amsterdam, J D ^a   Fawcett, J ^a   Quitkin, F M ^a   Reimherr, F W ^a   Rosenbaum, J F ^a   Beasley, C M ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORFLUOXETINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LETTER; PRIORITY JOURNAL; STEADY STATE;

DEPRESSION; FLUOXETINE; HUMANS; SEROTONIN UPTAKE INHIBITORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0035195659     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200112000-00014     Document Type: Letter

References (18)

1. Clinical pharmacology and pharmacokinetics of fluoxetine: A review
2. Sustained plasma concentrations of fluoxetine and/or norfluoxetine four and eight weeks after fluoxetine discontinuation
3. Fluoxetine and norfluoxetine plasma levels after treatment discontinuation in man
4. Fluoxetine and norflu-oxetine plasma levels in major depression: A multi-center study
5. Optimal length of continuation therapy in depression: A prospective assessment during long-term fluoxetine treatment
6. Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection
7. Fluoxetine kinetics and protein binding in normal and impaired renal function
8. Norfluoxetine enantiomers as inhibitors of serotonin uptake in rat brain
9. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine
10. Simultaneous determination of fluoxetine and norfluoxetine enantiomers in biological samples by gas chromatography with electron-capture detection
11. Simultaneous determination of plasma levels of fluvoxamine and of the enantiomers of fluoxetine and norfluoxetine by gas chromatography-mass spectrometry
12. Safety of abrupt discontinuation of fluoxetine: A randomized, placebo-controlled study
13. Weekly dosing of fluoxetine for the continuation phase of treatment of major depression: Results of a placebo-controlled, randomized clinical trial
14. Pharmacokinetics of the newer antidepressants: Clinical relevance
15. Danger of MAOI therapy after fluoxetine withdrawal
16. Adverse consequences of fluoxetine-MAOI combination therapy
17. Possible monoamine-oxidase inhibitor serotonin uptake inhibitor interaction - Fluoxetine clinical-data and preclinical findings
18. Detectable levels of fluoxetine metabolites after discontinuation: An unexpected serotonin syndrome